627 related articles for article (PubMed ID: 18457473)
1. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to B-lymphocyte stimulator.
Drugs R D; 2008; 9(3):197-202. PubMed ID: 18457473
[TBL] [Abstract][Full Text] [Related]
2. Belimumab Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline.
Ding C; Jones G
Curr Opin Investig Drugs; 2006 May; 7(5):464-72. PubMed ID: 16729724
[TBL] [Abstract][Full Text] [Related]
3. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
4. Belimumab: anti-BLyS monoclonal antibody; Benlysta; BmAb; LymphoStat-B.
Drugs R D; 2010; 10(1):55-65. PubMed ID: 20509716
[TBL] [Abstract][Full Text] [Related]
5. Influenza virus vaccine live intranasal--MedImmune vaccines: CAIV-T, influenza vaccine live intranasal.
Drugs R D; 2003; 4(5):312-9. PubMed ID: 12952502
[TBL] [Abstract][Full Text] [Related]
6. Belimumab, a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Espinosa G; Cervera R
Drugs Today (Barc); 2010 Dec; 46(12):891-9. PubMed ID: 21589946
[TBL] [Abstract][Full Text] [Related]
7. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus.
Furie R; Stohl W; Ginzler EM; Becker M; Mishra N; Chatham W; Merrill JT; Weinstein A; McCune WJ; Zhong J; Cai W; Freimuth W;
Arthritis Res Ther; 2008; 10(5):R109. PubMed ID: 18786258
[TBL] [Abstract][Full Text] [Related]
8. Breaking the ice in systemic lupus erythematosus: belimumab, a promising new therapy.
Mosak J; Furie R
Lupus; 2013 Apr; 22(4):361-71. PubMed ID: 23553779
[TBL] [Abstract][Full Text] [Related]
9. Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus.
Wiglesworth AK; Ennis KM; Kockler DR
Ann Pharmacother; 2010 Dec; 44(12):1955-61. PubMed ID: 21081710
[TBL] [Abstract][Full Text] [Related]
10. Belimumab for the treatment of systemic lupus erythematosus.
Jordan N; D'Cruz DP
Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
[TBL] [Abstract][Full Text] [Related]
11. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
Furie R; Petri M; Zamani O; Cervera R; Wallace DJ; Tegzová D; Sanchez-Guerrero J; Schwarting A; Merrill JT; Chatham WW; Stohl W; Ginzler EM; Hough DR; Zhong ZJ; Freimuth W; van Vollenhoven RF;
Arthritis Rheum; 2011 Dec; 63(12):3918-30. PubMed ID: 22127708
[TBL] [Abstract][Full Text] [Related]
12. ISA 247: trans-ISA 247, trans-R 1524, ISA(TX)247, ISAtx 247, ISATx247, LX 211, LX211, R 1524, R-1524.
Drugs R D; 2007; 8(2):103-12. PubMed ID: 17324008
[TBL] [Abstract][Full Text] [Related]
13. Belimumab--an anti-BLyS human monoclonal antibody for rheumatoid arthritis.
Jin X; Ding C
Expert Opin Biol Ther; 2013 Feb; 13(2):315-22. PubMed ID: 23268610
[TBL] [Abstract][Full Text] [Related]
14. BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.
Fairfax K; Mackay IR; Mackay F
IUBMB Life; 2012 Jul; 64(7):595-602. PubMed ID: 22641424
[TBL] [Abstract][Full Text] [Related]
15. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
Jordan NP; D'Cruz DP
Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
[TBL] [Abstract][Full Text] [Related]
16. Belimumab: a BLyS-specific inhibitor for the treatment of systemic lupus erythematosus.
Dennis GJ
Clin Pharmacol Ther; 2012 Jan; 91(1):143-9. PubMed ID: 22130121
[TBL] [Abstract][Full Text] [Related]
17. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
18. Targeting BLyS in systemic lupus erythematosus.
Liu Y; La Cava A
Recent Pat Inflamm Allergy Drug Discov; 2012 May; 6(2):91-6. PubMed ID: 22216778
[TBL] [Abstract][Full Text] [Related]
19. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
Harvey PR; Gordon C
BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]